NZ592998A - Depot formulation comprising oxtreotide and two linear polylactide-co-glycolide polymers (PLGAs) - Google Patents
Depot formulation comprising oxtreotide and two linear polylactide-co-glycolide polymers (PLGAs)Info
- Publication number
- NZ592998A NZ592998A NZ592998A NZ59299809A NZ592998A NZ 592998 A NZ592998 A NZ 592998A NZ 592998 A NZ592998 A NZ 592998A NZ 59299809 A NZ59299809 A NZ 59299809A NZ 592998 A NZ592998 A NZ 592998A
- Authority
- NZ
- New Zealand
- Prior art keywords
- polymers
- plgas
- tumours
- glycolide
- depot formulation
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 title abstract 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 abstract 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 abstract 1
- 206010007275 Carcinoid tumour Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 108010016076 Octreotide Proteins 0.000 abstract 1
- 208000009311 VIPoma Diseases 0.000 abstract 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 abstract 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000011010 flushing procedure Methods 0.000 abstract 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 abstract 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000009115 maintenance therapy Methods 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 229960002700 octreotide Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08171712 | 2008-12-15 | ||
| PCT/EP2009/067049 WO2010079047A2 (en) | 2008-12-15 | 2009-12-14 | Octreotide depot formulation with constantly high exposure levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ592998A true NZ592998A (en) | 2013-02-22 |
Family
ID=40520410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ592998A NZ592998A (en) | 2008-12-15 | 2009-12-14 | Depot formulation comprising oxtreotide and two linear polylactide-co-glycolide polymers (PLGAs) |
Country Status (25)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ591810A (en) | 2008-09-17 | 2012-12-21 | Chiasma Inc | Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid |
| RU2695522C2 (ru) * | 2012-05-14 | 2019-07-23 | Тейдзин Лимитед | Стерильная композиция |
| PT3125871T (pt) * | 2014-03-31 | 2021-01-06 | Pharmathen Sa | Preparação de microsferas de plga carregadas com péptido com características de libertação controlada |
| IL285440B1 (en) | 2014-12-10 | 2025-09-01 | Amryt Endo Inc | Oral preparations containing octreotide in combination with other medicinal substances for the treatment of acromegaly |
| EP4527456A3 (en) | 2015-02-03 | 2025-05-21 | Amryt Endo, Inc. | Treating acromegaly with oral octreotide |
| CN105963258B (zh) | 2016-04-26 | 2021-01-22 | 广州帝奇医药技术有限公司 | 一种缓释微粒的制备方法 |
| KR102142026B1 (ko) * | 2017-05-31 | 2020-08-06 | 주식회사 대웅제약 | 방출제어가 용이한 서방성 약물 미립자의 제조방법 |
| KR20250004925A (ko) | 2017-09-15 | 2025-01-08 | 옥슬러 리미티드 | 안과용 약물 조성물 |
| JP7704740B2 (ja) | 2019-09-16 | 2025-07-08 | アムジエン・インコーポレーテツド | 薬物送達デバイスの外部滅菌の方法 |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| GB9513224D0 (en) * | 1995-06-29 | 1995-09-06 | Sandoz Ltd | Organic compounds |
| KR20050088288A (ko) * | 2002-11-06 | 2005-09-05 | 알자 코포레이션 | 제어식 방출 데포 제형 |
| US20040097419A1 (en) * | 2002-11-19 | 2004-05-20 | Holger Petersen | Organic compounds |
| GB0326602D0 (en) * | 2003-11-14 | 2003-12-17 | Novartis Ag | Organic compounds |
| MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
| US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
| JP2008524235A (ja) * | 2004-12-15 | 2008-07-10 | キューエルティー ユーエスエー，インコーポレイテッド． | オクトレオチド化合物の徐放性送達処方物 |
| ES2492641T3 (es) * | 2005-12-22 | 2014-09-10 | Novartis Ag | Formulación de liberación sostenida que comprende octreótida y dos o más polímeros de poliláctida-co-glicólido |
-
2009
- 2009-12-11 AR ARP090104820A patent/AR074603A1/es unknown
- 2009-12-11 US US12/635,761 patent/US20100151033A1/en not_active Abandoned
- 2009-12-14 CN CN201510542720.5A patent/CN105233251A/zh active Pending
- 2009-12-14 PL PL09799316T patent/PL2376070T3/pl unknown
- 2009-12-14 CA CA2746968A patent/CA2746968C/en not_active Expired - Fee Related
- 2009-12-14 NZ NZ592998A patent/NZ592998A/xx not_active IP Right Cessation
- 2009-12-14 KR KR1020117016340A patent/KR101708517B1/ko not_active Expired - Fee Related
- 2009-12-14 SG SG2011034345A patent/SG171255A1/en unknown
- 2009-12-14 WO PCT/EP2009/067049 patent/WO2010079047A2/en not_active Ceased
- 2009-12-14 CN CN201510542237.7A patent/CN105031607A/zh active Pending
- 2009-12-14 BR BRPI0922607-9A patent/BRPI0922607B1/pt not_active IP Right Cessation
- 2009-12-14 RU RU2011128538/15A patent/RU2526822C2/ru active
- 2009-12-14 EP EP09799316.6A patent/EP2376070B1/en active Active
- 2009-12-14 CN CN2009801503147A patent/CN102245210A/zh active Pending
- 2009-12-14 MY MYPI2011002392A patent/MY159789A/en unknown
- 2009-12-14 US US13/133,968 patent/US20110262545A1/en not_active Abandoned
- 2009-12-14 MX MX2011006335A patent/MX2011006335A/es active IP Right Grant
- 2009-12-14 PT PT97993166T patent/PT2376070T/pt unknown
- 2009-12-14 PE PE2011001218A patent/PE20110876A1/es active IP Right Grant
- 2009-12-14 JP JP2011540134A patent/JP5721635B2/ja active Active
- 2009-12-14 ES ES09799316.6T patent/ES2602614T3/es active Active
- 2009-12-14 AU AU2009336718A patent/AU2009336718B9/en not_active Ceased
- 2009-12-14 MA MA34011A patent/MA32964B1/fr unknown
-
2011
- 2011-05-19 IL IL213034A patent/IL213034A/en active IP Right Grant
- 2011-05-23 TN TN2011000261A patent/TN2011000261A1/fr unknown
- 2011-06-14 CL CL2011001438A patent/CL2011001438A1/es unknown
- 2011-06-15 CO CO11074834A patent/CO6382109A2/es not_active Application Discontinuation
- 2011-07-13 EC EC2011011199A patent/ECSP11011199A/es unknown
-
2014
- 2014-08-25 US US14/467,212 patent/US20140363513A1/en not_active Abandoned
-
2015
- 2015-12-09 US US14/964,079 patent/US20160089336A1/en not_active Abandoned
-
2017
- 2017-01-10 US US15/402,657 patent/US20170143791A1/en not_active Abandoned
- 2017-10-19 US US15/788,047 patent/US20180036230A1/en not_active Abandoned
-
2019
- 2019-03-14 US US16/352,986 patent/US20190209462A1/en not_active Abandoned
-
2021
- 2021-02-09 US US17/171,836 patent/US20210161806A1/en not_active Abandoned
-
2023
- 2023-04-27 US US18/308,597 patent/US20240082148A1/en not_active Abandoned
-
2024
- 2024-08-08 US US18/797,888 patent/US20250205147A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ592998A (en) | Depot formulation comprising oxtreotide and two linear polylactide-co-glycolide polymers (PLGAs) | |
| ZA202202410B (en) | Rna particles comprising polysarcosine | |
| EP2567971A3 (en) | Peptide vaccines comprising Seq Id 80, 100 or 101 for cancers expressing tumor-associated antigens | |
| IN2012DN00407A (cg-RX-API-DMAC7.html) | ||
| NZ607797A (en) | Corticosteroids for the treatment of joint pain | |
| EP2933264A3 (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| PE20142332A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| CA2534997A1 (en) | Methods for administering aripiprazole | |
| EP2371853A3 (en) | Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment | |
| WO2008021548A3 (en) | Epoxy-containing poly(ester amides) and methods of use | |
| MX343499B (es) | Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento. | |
| WO2011149964A3 (en) | Methods for treating or preventing vascular graft failure | |
| AR033671A1 (es) | Composicion farmaceutica acuosa del tipo de gel para administracion subcutanea, procedimiento para su preparacion y el uso de dicha composicion para la preparacion de un medicamento | |
| CN1649645A (zh) | 用于治疗肾癌的缩酚肽 | |
| NZ781622A (en) | Method of treating a child with central precocious puberty using an extended release composition | |
| MXPA05010613A (es) | Formulacion parenteral de acido micofenolico, una sal o profarmaco del mismo. | |
| WO2012049324A3 (en) | New emd formulation comprising pga | |
| WO2021113207A3 (en) | Percutaneous sling for papillary muscle approximation | |
| CY1106617T1 (el) | Φαρμακευτικη συνθεση περιλαμβανουσα συμπλοκο ψευδαργυρου-υαλουρονικου για τη θεραπεια σκληρυνσης κατα πλακας | |
| Matarasso | The use of injectable collagens for aesthetic rejuvenation | |
| BR0213821A (pt) | Conjugados de polìmero/peptìdeo timosina alfa 1 | |
| WO2005014032A3 (en) | Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite | |
| WO2010020972A8 (en) | Implant device | |
| US20220111119A1 (en) | Host modulating and tissue regenerative hydrogel compositions and methods of their delivery to periodontal and peri-implant tissues | |
| WO2009070564A3 (en) | Compositions and methods for prevention of infection in transcutaneous osseointegrated implants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 DEC 2016 BY CPA GLOBAL Effective date: 20131101 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 DEC 2017 BY CPA GLOBAL Effective date: 20161118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 DEC 2018 BY CPA GLOBAL Effective date: 20171116 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 DEC 2019 BY CPA GLOBAL Effective date: 20181122 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 DEC 2020 BY CPA GLOBAL Effective date: 20191121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 DEC 2021 BY CPA GLOBAL Effective date: 20201119 |
|
| LAPS | Patent lapsed |